GHS Peptides GHRP-2 and GHRP-6 Rejuvenate GH/IGF-1 Axis via Four Simultaneous Mechanisms in Elderly
Background
Age-related decline of the GH/IGF-1 axis drives loss of bone mineral density, lean body mass, and physical function in elderly populations, yet no orally bioavailable agent existed to safely restore physiological GH pulse amplitude. The GHS-R (growth hormone secretagogue receptor) and its endogenous ligand were both unknown at the outset of this research program, meaning drug development had to proceed entirely on functional grounds — a rare reverse-pharmacology challenge. Standard recombinant GH therapy requires injection, does not reproduce natural pulsatile release, and carries supraphysiological-exposure risks. A small molecule capable of once-daily oral dosing that faithfully mimics youthful GH secretion patterns represented a major unmet need across endocrinology, geriatrics, and sports medicine.
Study Design
GH secretagogues (GHS), including peptide leads GHRP-2 and GHRP-6 alongside the orally active small molecule MK-677, were developed through reverse pharmacology — using functional GH-release assays as the primary screen before the receptor was identified. Studies spanned cell-based somatotroph models, elderly human subjects (GH/IGF-1 profiling, bone mineral density, lean mass, strength), and old mouse models (thymic function). The GHS-R was subsequently identified by expression cloning; ghsr-knockout mouse studies were employed to confirm that GHS compounds are ghrelin mimetics.
Results
GHS compounds were shown to act simultaneously through four distinct mechanisms: increasing GHRH release, amplifying GHRH signaling in anterior pituitary somatotrophs, reducing somatostatin release, and antagonizing somatostatin receptor signaling — an unusually broad mechanistic footprint for a single compound class. In elderly human subjects, GHS administration reproduced a young adult physiological GH profile, confirming successful axis rejuvenation.
Restoration of a young adult GH secretion profile in elderly subjects was accompanied by increased bone mineral density, increased lean mass, modest improvements in strength, and improved recovery from hip fracture.
In old mice, GHS treatment induced restoration of thymic function, extending the observed benefits beyond the musculoskeletal system into immune biology. Expression cloning of the GHS-R revealed a previously unknown G protein-coupled receptor expressed predominantly in brain, pituitary gland, and pancreas. Exploitation of the cloned GHS-R identified two endogenous ligands: ghrelin (full agonist) and adenosine (partial agonist), completing the reverse-pharmacology cycle.
Key Findings
- GHS act via four simultaneous mechanisms: increased GHRH release, amplified GHRH signaling, reduced somatostatin release, somatostatin receptor antagonism.
- Elderly subjects treated with GHS achieved a young adult physiological GH/IGF-1 secretion profile.
- Outcomes in elderly humans included increased bone mineral density, increased lean mass, modest strength gains, and improved hip fracture recovery.
- Old mice showed restoration of thymic function following GHS treatment.
- GHS-R identified as a novel GPCR; ghrelin confirmed as full endogenous agonist, adenosine as partial agonist via ghsr-knockout mouse studies.
Why It Matters
GHS compounds including GHRP-2, GHRP-6, and MK-677 target four converging GH-axis nodes simultaneously, which explains their superior efficacy over single-mechanism secretagogues and provides a pharmacological rationale for their clinical and off-label use in aging, body composition, and recovery contexts. The demonstration of improved hip fracture recovery and restored thymic function in addition to lean-mass and bone-density gains broadens the potential clinical target population well beyond aesthetics. For clinicians and informed users, the mechanistic redundancy means GHS likely remain effective even when one pathway is attenuated, as seen in partial somatostatin dysregulation states common in older adults. The identification of ghrelin as the endogenous GHS-R agonist anchors these peptides to a validated physiological system, strengthening the translational case compared to purely synthetic receptor agonists with no known natural counterpart.
